Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Congress Expands Probe Into Ranbaxy’s AIDS Drugs Supplied To Developing Nations

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Four leaders of the U.S. Congressional Committee on Energy and Commerce - John Dingell, Bart Stupak, Joe Barton and John Shimkus have expanded their investigations into U.S. FDA's handling of Ranbaxy's anti-AIDS drugs that are supplied to African and other developing nations as part of the President's Emergency Plan for AIDS Relief program

You may also be interested in...



Ranbaxy Gets U.S. FDA Nod For Imitrex After Four Months Of Waiting

MUMBAI - Four months after the U.S. FDA imposed an import alert on 33 products manufactured by Ranbaxy, the company received a much needed shot in the arm after the drug regulator approved launch of its generic versions of GlaxoSmithKline's migraine drug Imitrex (sumatriptan) 100 mg, which has sales of over $1.1 billion in the U.S. alone

Ranbaxy Gets U.S. FDA Nod For Imitrex After Four Months Of Waiting

MUMBAI - Four months after the U.S. FDA imposed an import alert on 33 products manufactured by Ranbaxy, the company received a much needed shot in the arm after the drug regulator approved launch of its generic versions of GlaxoSmithKline's migraine drug Imitrex (sumatriptan) 100 mg, which has sales of over $1.1 billion in the U.S. alone

As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened

Indian generics manufacturer Ranbaxy Laboratories' tangle with U.S. FDA is persisting and will likely impact U.S. sales in 2009

Related Content

UsernamePublicRestriction

Register

SC069606

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel